Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation treatment study for prior elotuzumab trial participants
jRCT2031210116Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of elotuzumab in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoints: Number of subjects treated and Duration of treatment. Started Jul 2021; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031210116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210116.